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Background: Surveillance of integrity of the basic elements of the cell including DNA, RNA, and proteins is a critical
element of cellular physiology. Mechanisms of surveillance of DNA and protein integrity are well understood.
Surveillance of structural RNAs making up the vast majority of RNA in a cell is less well understood. Here, we
sought to explore integrity of processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and
other inflammatory diseases.
Results: We employed mononuclear cells obtained from subjects with RRMS and cell lines. We used quantitative-PCR
and whole genome RNA sequencing to define defects in structural RNA surveillance and siRNAs to deplete target
proteins. We report profound defects in surveillance of structural RNAs in RRMS exemplified by elevated levels of
poly(A) + Y1-RNA, poly(A) + 18S rRNA and 28S rRNAs, elevated levels of misprocessed 18S and 28S rRNAs and
levels of the U-class of small nuclear RNAs. Multiple sclerosis is also associated with genome-wide defects in
mRNA splicing. Ro60 and La proteins, which exist in ribonucleoprotein particles and play different roles in quality
control of structural RNAs, are also deficient in RRMS. In cell lines, silencing of the genes encoding Ro60 and La
proteins gives rise to these same defects in surveillance of structural RNAs.
Conclusions: Our results establish that profound defects in structural RNA surveillance exist in RRMS and
establish a causal link between Ro60 and La proteins and integrity of structural RNAs.Background
Relapsing remitting multiple sclerosis (RRMS) affects ap-
proximately 0.1% of the population. RRMS is characterized
by de-myelination of neurons but disease mechanisms are
incompletely understood. Involvement of innate and
adaptive arms of the immune system is detected in in-
flammatory demyelinating lesions implicating these in
pathogenesis. Both genetic and environmental factors
are also implicated in the origins of RRMS [1-8].
Studies have demonstrated an expanding complexity
of non-protein-coding RNAs (ncRNA) in higher eukary-
otes [9]. Non-vertebrate metazoans and microbes pos-
sess a single Y RNA while humans encode up to four Y
RNAs, termed Y1, Y3, Y4, and Y5 RNA [10]. Y RNAs
are approximately 100 nucleotides in length and are* Correspondence: tom.aune@vanderbilt.edu
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unless otherwise stated.transcribed by RNA polymerase III. Y RNAs possess
sequence-specific binding sites for the Ro60 protein [11].
All four human Y RNAs assemble into ribonucleopro-
tein (RNP) particles including Ro60, La, and other pro-
teins [12]. Precise functions of Y RNAs and Ro
nucleoprotein particles are incompletely understood but
studies suggest they contribute to ncRNA quality control
and ribosomal RNA (rRNA) processing [13,14]. To pro-
duce mature rRNAs, RNA polymerase 1 transcribes a
47S precursor rRNA that is processed via endonucleo-
lytic, exonucleolytic, and additional modifications produ-
cing mature 5.8S, 18S, and 28S rRNAs [15-17]. Small
nuclear U RNAs are another form of ncRNA making up
the RNA portion of the RNP complex known as the spli-
ceosome required for splicing of pre-mRNAs to mature
mRNAs [18,19]. In vertebrates, major small nuclear U
RNAs include U1, U2, U4, U5, and U6 [20,21]. Defects
or mutations in specific small nuclear U RNAs or the
genes encoding proteins required for biogenesis of U-
RNA RNP complexes, such as SMN1 (survival of motorl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Spurlock et al. Genome Biology  (2015) 16:58 Page 2 of 13neuron 1), give rise to specific neurodegenerative disor-
ders rather than global defects [22-26].
Polyadenylation of mRNAs at the 3’ end is a necessary
step in their synthesis and maturation [14,19,27-32]. Ma-
ture, fully processed ncRNAs lack 3’ poly(A) tails.
Addition of poly(A) tails to ncRNAs represents a critical
quality-control step to promote degradation of mis-
folded or mis-processed ncRNAs. Specific protein com-
plexes exist to add poly(A) tails to RNA substrates to
promote their degradation by stimulating exonucleolytic
activity of the exosome thus leading to degradation of
mis-processed or mis-folded ncRNAs.
It is fundamentally unknown how normal cellular pro-
cesses or responses to extracellular stimuli may invoke
polyadenylation and degradation of ncRNA substrates or
if human disease processes exhibit defects in polyadeny-
lation of ncRNA substrates as part of their pathogenesis.
Here, our results demonstrate that mononuclear cells
from subjects with RRMS exhibit pervasive increases in
levels of polyadenylated ncRNAs including Y1 RNA, 18S
and 28S rRNA, and U1, U2, and U4 snRNAs and these
defects are unique to RRMS. Defects in expression of
both Ro60 and La proteins in RRMS appear to contrib-
ute to increased polyadenylation of ncRNAs. Further,
IFN-β1b, a common RRMS therapy [33], restores both
Ro60 and La levels to normal as well as levels of polya-
denylated Y1 RNA and U1 snRNA suggesting that aber-
rant polyadenylation of ncRNA substrates may have
pathogenic consequences.
Results
Elevated polyadenylation of ncRNA substrates in RRMS
To initiate our studies, we determined levels of Y RNAs
in different subject cohorts by quantitative PCR using ei-
ther random hexamers or oligo-dT for synthesis reason-
ing that random hexamers should allow amplification of
all Y RNAs independent of whether or not they were
polyadenylated but that oligo-dT would allow amplifica-
tion of only those Y RNAs that were polyadenylated con-
sistent with previously established methodologies [31].
We also confirmed that >95% of total cellular Y RNAs
were retained during the PaxGene total RNA isolation
procedure. Sanger sequencing of the PCR products con-
firmed identity of all human Y RNAs. We found that
levels of total Y RNAs (random hexamers) were not
markedly different between CTRL and RRMS subjects
(Figure 1A). In marked contrast, levels of polyadenylated
Y1 RNA (oligo-dT), but not other Y RNAs, were in-
creased by about 20-fold in RRMS relative to CTRL
(Figure 1B). This elevation of polyadenylated Y1 RNA
was not seen in systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), neuromyelitis optica (NMO),
or Parkinson’s disease (PD) (Additional file 1: Table S1
for a description of subjects) (Figure 1C). In a cross-sectional analysis, we compared levels of polyadenylated
Y1 RNA in blood samples obtained from subjects ex-
periencing a first clinically isolated syndrome who went
on to develop RRMS at a later date (CIS-MS), from sub-
jects at the time of their diagnosis of RRMS but prior to
onset of any therapies (RRMS-NAÏVE) and from subjects
with RRMS of >1 year’s duration (RRMS) (Figure 1D). We
found that levels of polyadenylated Y1 RNA were elevated
in both RRMS-NAÏVE and RRMS cohorts but that levels
of polyadenylated Y1 RNA were similar to CTRL levels in
the CIS-MS cohort. Thus, increased polyadenylation of
Y1 RNA, but not other Y RNAs, was observed in RRMS,
but not other autoimmune diseases.
We used a similar approach to measure levels of total
and polyadenylated 18S and 28S rRNAs. We found that
levels of total 18S and 28S rRNAs were similar between
the RRMS and CTRL cohorts when random hexamers
were used for cDNA synthesis (Figure 2A). However, we
found a marked increase in levels of both polyadenylated
18S and 28S rRNAs as measured by employing oligo-dT
for cDNA synthesis (Figure 2B). We therefore deter-
mined if there was also an increase in misprocessed
rRNAs in RRMS since rRNAs are polyadenylated in the
presence of defective processing of the 18S and 28S
rRNAs from their 47S rRNA precursor. We predicted
that misprocessing of rRNAs should produce 18S and
28S rRNAs longer than the typical 1.9 kb and 5.0 kb, re-
spectively. To test this hypothesis, we designed a series
of PCR primers to probe lengths of 18S and 28S rRNAs.
We used common primers within the 18S or 28S rRNA
(black arrows) and four additional primers; one within
the classic 18S or 28S rRNA (green and blue arrows)
and three that extend 30, 60, or 90 bp beyond the length
of the fully processed 1.9 kb 18S or 5 kb 28S rRNA tran-
script (orange and red arrows) (Figure 2C). Random
hexamers were used for cDNA synthesis. We found that
18S and 28S transcript levels in CTRL and RRMS were
approximately the same (normalized to 1), labeled 18S
(Figure 2D, left) or 28S (Figure 2D, right), when PCR
primers within the 1.9 kb 18S rRNA or 5.0 kb 28S rRNA
were employed. However, when we employed an internal
primer (black arrow) and external primers 30, 60, or 90 bp
distal to the normal transcript size (orange arrows, red ar-
rows) we found a marked increase in transcript levels of
18S rRNA with extended ends between 30 and 90 bp in
RRMS compared to CTRL. These 18S rRNA extended ends
were more frequent at the 5’ end of the 18S rRNA than the
3’ end of the 18S rRNA. The 28S rRNA had only a modest
increase in extended ends in RRMS relative to CTRL at the
5’ end. For the 28S RNA species, the increase in the fre-
quency of extended ends in RRMS relative to CTRL was
more pronounced at the 3’ end. We interpret these results
to demonstrate that both 18S rRNAs and 28S rRNAs were
not accurately processed to their mature size in RRMS.





























































































Figure 2 Increased polyadenylation and mis-processing of 18S and 28S rRNAs in RRMS. (A) Total rRNA levels in blood determined after cDNA
synthesis using random hexamers in CTRL (N = 24) and RRMS (N = 22). (B) As in (A) except oligo-dT was used for cDNA synthesis. (C) Schematic
illustrating PCR strategy to detect misprocessed 18S and 28S rRNAs. (D) Transcript levels of misprocessed rRNAs (-90, -60, -30) in RRMS (N = 12) relative























































































































Figure 1 Increased levels of poly(A) + Y1 RNA in RRMS. (A) Total Y RNA levels in peripheral whole blood determined after cDNA synthesis using
random hexamers in CTRL (N = 24) and RRMS (N = 22). (B) As in (A) except oligo-dT was used for cDNA synthesis. (C) As in (B) except different
disease cohorts. Individual transcripts were normalized to GAPDH transcript levels in CTRL (N = 24), SLE (N = 24), RA (N = 18), NMO (N= 22), and PD
(N = 19). (D) Total poly(A) + Y1 RNA levels were determined using oligo-dT in CTRL (N = 24), CIS-MS (N = 16), RRMS-NAÏVE (N = 24), and RRMS (N = 22).
Error bars are S.D. *P <0.05, **P <0.005.
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tubes) from CTRL subjects, subjects with RRMS or
with other inflammatory diseases. As above, synthesis
of cDNA was performed using random hexamers and
oligo-dT and transcript levels were determined by
quantitative PCR. We found a modest increase in total
levels of U1 RNA (random hexamers) in RRMS relative
to CTRL (Figure 3A). In contrast, poly(A) + U1 tran-
script levels were markedly elevated in subjects with
RRMS relative to CTRL (Figure 3B). The CIS-MS co-
hort did not exhibit increased poly(A) + U1 RNA levels
nor did subjects with other inflammatory diseases, SLE,
RA, and NMO. We also extracted RNA-seq data and
confirmed that poly(A) + U1 RNA levels were elevated
in RRMS and that U2 and U4 RNA levels were also ele-
vated in RRMS relative to CTRL (Figure 3C). We also
examined expression of total and poly(A) + U11 and
U12 transcripts, components of the minor spliceosome
pathway, and found elevated poly(A) + U11 and U12
transcript levels in RRMS versus CTRL and increased
total U11 transcript levels. Total levels of U12 snRNA
were not significantly different between RRMS and
CTRL (Figure 3D). Thus, multiple ncRNA species ex-
hibit increased polyadenylation in RRMS relative to
CTRL or other autoimmune diseases.
Alterations in mRNA processing in RRMS
The U1, U2, U4, U5, and U6 RNAs play critical roles in
determining mRNA length and isoform expression via
several mechanisms including protection from prema-
ture cleavage and polyadenylation of nascent pre-
mRNAs [21,26,34]. Disruption of levels of individual U
RNAs is sufficient to cause global alterations in alterna-
tive splicing and mRNA length. It is not known how im-
balances or altered polyadenylation of multiple U
snRNAs may impact alternative splicing and mRNA
































































Figure 3 Increased total and polyadenylated U snRNAs in RRMS. (A) Total
random hexamers for cDNA synthesis in CTRL (N = 24) and RRMS (N = 22).
(B) As in (A) except total poly(A) + U1 snRNA levels were determined by qu
CIS-MS (N = 16), RRMS (N = 22), SLE (N = 24), RA (N = 18), and NMO (N = 22)
genome RNA-sequencing (RNA-seq) and normalized to CTRL = 1; CTRL (N =
and U12 snRNAs were determined by quantitative PCR using oligo d(T) forby loss of 5’ or 3’ exons, choice of alternative 5’ and 3’
UTRs, choice of initial and final exons and partial reten-
tion of intron sequences, we searched our RNA-seq data
for differences in splicing and intron retention between
CTRL subjects and subjects with RRMS. For each
chromosome, we counted the number of reads per exon
across the genome in CTRL and RRMS subjects. We
found a genome-wide loss of exon expression in RRMS
relative to CTRL (Figure 4A). Genome-wide analysis of
expressed genes demonstrated that 17% of transcribed
genes exhibited loss of 5’ exons (5’ shortening) (Figure 4B).
Loss of 3’ exons (3’ shortening, 3% of transcribed genes)
was less frequent. Intron retention was also less frequent
and only 4% of transcribed genes exhibited forms of intron
retention. Visual inspection of 3,000 or 30% of expressed
genes using the Integrative Genome Viewer (IGV) con-
firmed these results. We defined 5’ and 3’ shortening to
mean that at least one exon at the 5’ or 3’ end of the tran-
script, respectively, exhibited a >5-fold reduction in
expressed counts or FPKM relative to exons at the 3’ or 5’
end of the transcript, respectively, in RRMS subjects com-
pared to CTRL subjects. Intron retention was similarly de-
fined as an increase in read counts localized to an intron
by >5-fold in RRMS compared to CTRL subjects. The ma-
jority of genes transcribed in mononuclear cells from
RRMS compared to CTRL did not display differences in
isoform distribution or retention of intron sequences.
We analyzed the number of read counts per intron
and found that subjects with RRMS exhibited higher in-
tron read counts across chromosomes compared to
CTRL. Examples of these alterations included MBP,
CSF1R, and NFATC1 (Figure 4C to E). We found that
the myelin basic protein gene, MBP, which encodes both
classic myelin basic protein expressed primarily by mye-
lin forming cells and a second family of proteins, called
golli proteins, expressed by T lymphocytes, neurons, and




















































U1 RNA transcript levels were determined by quantitative PCR using
Individual transcripts were normalized to GAPDH transcript levels.
antitative PCR using oligo-dT for cDNA synthesis in CTRL (N = 24),
. (C) As in (A), except transcript levels were determined by whole
8) and RRMS (N = 6). (D) As in (A, B) except transcript levels of U11
poly(A) + or random hexamer primers for total U11 or U12 snRNA.
NFATC15’ UTR 1st 3’UTR 2nd 3’UTR 
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Figure 4 Extensive mRNA isoform loss and intron retention in RRMS.
(A) Total exon loss and intron gain events across the genome in
RRMS (N = 6) and CTRL (N = 8) were determined from RNA-seq
analysis (see Methods). Results are expressed as average normalized
counts or reads across known exons and introns in CTRL and RRMS.
(B) Percent abundance of transcript alterations in RRMS relative to
CTRL PBMC determined from analysis of genome-wide RNA-seq
data. (C) Example of intron retention in mRNA encoded by MBP.
Green arrows identify exons. Red circles identify retention of intron
sequences in mature mRNA in RRMS. Orange and blue arrows
identify two isoforms. (D, E) Examples of 5’ mRNA shortening, CSF1R,
and 3’ mRNA shortening, NFATC1 in RRMS. Red arrows identify loss
of exons in RRMS and green arrows identify exons expressed at
equal levels between CTRL and RRMS. (F) Expression levels of individual
exons and the MBP intron in CTRL (N = 12) and RRMS (N = 12) was
determined by quantitative PCR and normalized to CTRL = 1.0 after
normalization to transcript levels of GAPDH, error bars are S.D. * = P <0.05.
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from right to left) [35-37]. Individual exons are labeled
with green arrows and regions of intron retention seen
in RRMS are labeled with red circles. Retained intron se-
quences were present in both ‘golli’ and ‘golli-MBP’
mRNAs; classic MBP gene depicted by the blue arrow,
golli-MBP gene depicted by the orange arrow. Thus, U
snRNA imbalance in RRMS was associated with intron
retention in MBP mRNA.
We also found a marked reduction in transcript levels
of the exons comprising CSF1R mRNAs. In CTRL sub-
jects, each of the 22 exons was present at approximately
equal abundance. However, in RRMS, there was de-
creased transcript abundance of exons 1 to 11 (green ar-
rows identify exons expressed at similar levels in CTRL
and RRMS and red arrows show exon loss) (Figure 4D).
Thus, U snRNA imbalance in RRMS was also associated
with 5’ shortening. 3’ shortening was also found in
RRMS (Figure 4E). All nine exons of NFATC1 mRNA
and the 3’ UTR exhibited similar transcript abundance
assembled into a continuous mRNA in CTRL subjects.
RRMS subjects exhibited a specific loss of the eighth
and ninth exons (note that the ninth exon is continuous
with the 3’ UTR, red arrows). The remaining expressed
exons were present at similar levels in CTRL and RRMS
(green arrows). We then validated these findings in a dif-
ferent cohort of CTRL and RRMS subjects using quanti-
tative PCR (Figure 4F). Transcript levels of MBP exon 4,
CSF1R exon 2, and NFATC1 exon 9 were significantly
reduced in RRMS versus CTRL. Levels of CSF1R exon
22 and NFATC1 exon 2 were only modestly reduced in
RRMS similar to our RNA-sequencing findings. We also
found increased transcript levels of the MBP intron be-
tween MBP exons 3 and 4 in RRMS compared to
CTRL. Thus, using both quantitative PCR and RNA-
sequencing, we were able to confirm specific examples
of intron retention, 5’ shortening, and 3’ shortening in
this independent sample set of RRMS subjects. These
Spurlock et al. Genome Biology  (2015) 16:58 Page 6 of 13shortened mRNA isoforms seen in RRMS are consist-
ent with mRNA premature cleavage and polyadenyla-
tion, a property that is produced by imbalances of U
snRNAs or loss of U snRNA function. U snRNA imbal-
ance observed in RRMS may contribute to intron reten-
tion as well as exon loss and mRNA shortening.
Reduced expression of Ro60 and La in RRMS
Ro60 and La proteins are components of ribonucleopro-
tein particles, bind discrete structural ncRNAs, and are
thought to play important roles in ncRNA processing
and quality control. For these reasons, we measured
TROVE2 (Ro60) and SSB (La) expression levels in blood
samples harvested in PaxGene tubes from the following
cohorts of subjects: CTRL, CIS-MS, RRMS, RA, SLE,
NMO, and PD. We found that TROVE2 and SSB tran-
script levels were markedly reduced in the established
RRMS cohort compared to CTRL. This difference was
unique to RRMS and not observed in other autoimmune
disease cohorts or in other inflammatory (NMO) or
non-inflammatory (PD) neurologic conditions (Figure 5A).
We replicated these findings by whole-genome RNA se-
quencing (RNA-seq) and obtained equivalent results
(Figure 5B). We also determined levels of protein ex-
pression of Ro60 and La in PBMC by western blotting.
We found that both Ro60 and La proteins were pro-
foundly diminished in RRMS PBMC relative to CTRL
PBMC (Figure 5C and D). Thus, both TROVE2 and SSB
transcripts and Ro60 and La proteins were profoundly
diminished in RRMS and these mRNA and protein ex-
pression differences were not seen in several other
autoimmune diseases.
Interferon-β1b (Betaseron) and structural defects in RRMS
For all analyses above, RRMS subjects were either on
copaxone or no immunomodulatory therapy. Thus, we
compared these subjects to RRMS on stable betaseron
therapy. We found that levels of TROVE2, SSB, poly(A) +
Y1 RNA and poly(A) + U1 snRNA were close to CTRL
levels in RRMS subjects on betaseron therapy compared
to RRMS subjects on either copaxone or no immunomod-
ulatory therapy (Figure 6A, B). We examined responses of
three individuals in longitudinal studies who initiated
betaseron and found that correction of levels of TROVE2,
SSB, poly(A) + Y1 RNA and poly(A) + U1 RNA was very
rapid. We hypothesize that signaling pathways either dir-
ectly or indirectly activated by betaseron interfere with
signaling pathways driving defects in polyadenylation of
structural RNAs in and expression of TROVE2 and SSB in
RRMS and that betaseron will be a useful tool to identify
underlying mechanisms. Further, measurement of polya-
denylated species of ncRNAs may provide a useful means
to monitor responses to betaseron or other immunomod-
ulatory therapies in RRMS.TROVE2 and SSB silencing disrupts structural RNA
surveillance and alters mRNA length
To establish causal links between Ro60 and La imbal-
ance and polyadenylation and processing of structural
ncRNAs observed in RRMS, we designed siRNAs spe-
cific for human TROVE2 and SSB and transfected them
into the human THP-1 monocyte or the Jurkat T cell
line. Transfection with TROVE2 siRNA caused specific
reduction of TROVE2 transcripts but not SSB transcripts
(Figure 7A). Similarly, the SSB siRNA caused specific
loss of SSB transcripts but not TROVE2 transcripts. We
asked if reduced TROVE2 or SSB levels resulted in an
increase in the amount of poly(A) + Y1 RNA in THP-1
cells. We found that knockdown of either TROVE2, SSB,
or the combination effectively increased levels of poly
(A) + Y1 RNA (Figure 7B). Additionally, knockdown of
SSB resulted in marked accumulation of poly(A) + 18S
rRNA (Figure 7C). Knockdown of TROVE2 resulted in
only a modest increase in poly(A) + 18S RNA. In con-
trast, levels of poly(A) + 28S rRNA were largely un-
affected by knockdown of either TROVE2 or SSB but
were modestly increased by the knockdown of both
TROVE2 and SSB. We also examined the impact of
TROVE2 or SSB knockdown on levels of poly(A) + U1
RNA and found that knockdown of TROVE2, but not
knockdown of SSB, caused a marked increase in levels of
poly(A) + U1 RNA (Figure 7D). rRNA misprocessing was
also analyzed as described above. In both THP-1 cells
and Jurkat cells, transfection of TROVE2 and/or SBB
siRNAs increased levels of misprocessed 18S rRNA and,
to a lesser extent, misprocessed 28S rRNA (Figure 7E, F).
Since the combination of TROVE2 and SSB knockdown
increased the amount of poly(A) + U1 RNA and alter-
ations in levels of U1 RNA result in isoform switching, we
determined if TROVE2 and SSB RNA knockdown was suf-
ficient to alter mRNA lengths in a cell [21]. We trans-
fected TROVE2 and SSB siRNAs into THP-1 cells and
employed a PCR strategy to test for different lengths of
MBP, CSF1R, and NFATC1 transcripts (Figure 7G).
Similar to what we observed in vivo, we found that re-
duced levels of either Ro60 or La by siRNA silencing
were sufficient to increase expression levels of the
MBP intron, to reduce expression of CSF1R exon 2 but
not CSF1R exon 22, and also decrease the ratio of
short to long NFATC1 isoforms (Figure 7H). Finally,
we examined the ability of Ro60 and La to bind these
target mRNAs using RNA immunoprecipitation and
quantitative PCR. Only a modest fraction of total
CSF1R, NFATC1, or MBP mRNA bound to Ro60 or La
(Additional file 2: Figure S1). Taken together, these re-
sults demonstrate that Ro60 and La protein levels are
critical for many aspects of proper RNA surveillance
including maintaining low levels of the poly(A) +
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Figure 5 Ro60 and La proteins are depressed in RRMS. (A) Ro60 (TROVE2) and La (SSB) transcript levels in CTRL (N = 24), CIS-MS (N = 16), RRMS
(N = 22), RA (N = 18), SLE (N = 24), NMO (N = 22), and PD (N = 19) were determined by quantitative PCR after cDNA synthesis using oligo-dT.
Results are normalized to CTRL = 1.0 after normalization to transcript levels of GAPDH, error bars are S.D. (B) As in (A) using whole genome
RNA-sequencing data. (C) Western blotting to determine Ro60 and La protein levels in PBMC from CTRL (N = 9) and RRMS (N = 8). (D) Quantitative
estimates of protein abundance relative to β-actin. *P <0.05, **P <0.01.
Spurlock et al. Genome Biology  (2015) 16:58 Page 7 of 13processing, and proper mRNA splicing; key compo-
nents of RNA function in the cell.
Discussion
We have found that extensive polyadenylation of struc-
tural RNAs, including Y1 RNA, U RNAs, and rRNAs is
a feature of mononuclear cells from subjects with RRMS
but not from subjects with other autoimmune or neuro-
degenerative conditions. Increased polyadenylation of
rRNAs is associated with mis-processing of both 18S
and 28S rRNAs. Alterations in polyadenylation and totalU RNAs, essential components of the spliceosome, are
associated with extensive 5’ shortening, 3’ shortening,
and intron retention of mRNAs. Ro60 and La, two pro-
tein components of ribonucleoprotein complexes in the
cell, are under-expressed in RRMS and siRNA-mediated
‘knockdown’ of Ro60 and/or La recapitulates these ef-
fects in cell lines resulting in increased polyadenylation
of structural RNAs, misprocessing of 18S and 28S
rRNAs, and isoform switching of mRNAs. Finally, IFN-
β1b or betaseron, a common therapy for RRMS, but not































































































Figure 6 Interferon-β1b (IFN-β1b) therapy corrects aberrant levels of TROVE2, SSB, poly (A) + Y1 RNA, and poly(A) + U1 snRNA in RRMS. Blood
samples were collected in PaxGene tubes from CTRL (N = 12), RRMS subjects not on IFN-β1b (RRMS - IFN-β1b, N = 12), and RRMS subjects on
stable IFN-β1b therapy (RRMS + IFN-β1b, N = 4). Oligo dT was used for cDNA synthesis. Transcript levels of TROVE2 and SSB (A) or poly(A) + Y1
RNA and poly(A) + U1 RNA (B) were determined by quantitative PCR and normalized to CTRL = 1 after normalization to levels of GAPDH. Error bars
are ± S.D. *P <0.05.
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the loss of Ro60 and La that is seen in RRMS.
A general model is that misfolded or misprocessed
RNA substrates are polyadenylated in ribonucleoprotein
particles, termed the Trf4p/Air2p/Mtr4p polyadenylation
complex or TRAMP complex in yeast [29]. Trf4p and
Trf5p are poly(A) polymerases. Mammalian orthologues
include PAPD5 and PAPD7. This complex or similar
complexes in higher eukaryotes catalyzes oligoadenyla-
tion or polyadenylation of RNA substrates, which, in
turn, stimulates the exosome to degrade these poly(A) +
substrates. Thus, in RRMS mononuclear cells, alter-
ations in levels of misfolded or misprocessed structural
RNAs or increased activity of the TRAMP complex or
its equivalent may lead to increased polyadenylation of
structural RNA substrates. Alternatively, decreased func-
tion of the exosome may lead to increased levels of poly
(A) + structural RNA substrates. In fact, the eubacterium
orthologue of Ro60 functions with Y RNA and the exo-
some to degrade misprocessed or misfolded structural
RNAs [38]. Thus, defects in expression of Ro60 in
RRMS may lead to defective function of the exosome
and contribute to increased levels of polyadenylated
structural RNAs seen in RRMS. Future studies will be
required to delineate among these possibilities.
Ribosomal RNA processing proceeds via both endonu-
cleolytic cleavages and exonucleolytic processing to yield
mature 18S and 28S rRNAs. Levels of misprocessed
rRNAs in cells are extremely low if effective RNA sur-
veillance mechanisms outlined above are fully functional.
Various manipulations, such as inhibition of RNA poly-
merase 1 by low concentrations of actinomycin D [30],
produce aberrant pre-rRNA transcripts that are polyade-
nylated. Thus, abortive synthesis and processing of 18Sand 28S rRNAs as well as other structural RNAs may
also contribute to increased levels of polyadenylated
structural RNAs in RRMS.
The U RNAs are another class of structural RNAs.
These snRNAs constitute the RNA portion of the spli-
ceosome required to remove introns from pre-mRNAs
to produce mature mRNAs for translation. Polyadeny-
lated forms of U1, U2, and U4 RNAs, as well as U11 and
U12 components of the minor spliceosome pathway, are
markedly increased in RRMS. There is also genome-
wide disruption of splicing and processing of mRNAs
resulting in 5’ and 3’ mRNA shortening and intron re-
tention. An example of intron retention is the MBP
gene. MBP has long been considered a candidate auto-
antigen for RRMS. In animal models, injection of foreign
MBP gives rise to cross-reactivity to native MBP and in-
flammation, autoimmunity and clinical symptoms simi-
lar to human RRMS [39]. In a similar vein, intron
retention in the MBP mRNA could produce MBP pro-
teins with altered C-termini viewed by the immune sys-
tem as foreign. Resulting immune responses to these
altered MBP proteins could lead to cross-reactivity with
native MBP and immune attack against myelin in the
central nervous system thus contributing to develop-
ment of RRMS.
Ro60 and La proteins are components of ribonucleo-
protein particles. Both proteins bind certain structural
RNAs. For example, Ro60 binds Y RNAs while La binds
tRNAs, certain rRNAs, and microRNAs [13]. Both pro-
teins are thought to play important roles in surveillance
and quality control of structural RNAs. We found that
both Ro and La proteins exhibit substantially reduced
expression in RRMS but not other autoimmune diseases




















































































































































































































































































































































































































































Figure 7 Loss of TROVE2 and/or SSB via small RNA interference increases poly(A) + Y1 RNA, rRNAs, and U1 RNA, misprocessed 18S and 28S rRNA,
and alters mRNA length. (A) Selective siRNA-mediated knockdown of TROVE2 or SSB in THP-1 cells or Jurkat T cells. Transcript levels of TROVE2
and SSB were determined by quantitative PCR using oligo d(T) for cDNA synthesis. Results are normalized to cells transfected with a non-specific
scrambled siRNA negative control after normalization to transcript levels of GAPDH. (B) Poly(A) + Y1 RNA levels were determined by quantitative
PCR using oligo-dT for cDNA synthesis. Results normalized to CTRL (transfection of scrambled siRNA). (C) As in (B) except levels of 18S and 28S
rRNAs were determined. (D) As in (B) except levels of poly(A) + U1 snRNA were determined. (E, F) Transcript levels of misprocessed rRNAs in
THP-1 (E) and Jurkat T cells (F) (-90, -60, -30 bp) were determined and are expressed relative to cells transfected with a scrambled siRNA as
described in Figure 2. (G) PCR strategy to test altered lengths of MBP, CSF1R, and NFATC1 transcripts. (H) As in (A) except transcript levels of the
MBP intron, CSF1R exons, and NFATC1 short to long mRNA isoform ratios were determined by quantitative PCR and normalized to CTRL. Each
experiment was performed a minimum of three times, results are expressed as mean ± S.D *P <0.05.
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La or both recapitulated many of the defects in struc-
tural RNA surveillance seen in RRMS mononuclear
cells. Thus, depletion of Ro60 and La proteins in RRMS
probably contributes to loss of structural RNA quality
control in RRMS. Exact mechanisms are not completely
clear. Ribonucleoprotein particles are heterogeneous
complex structures that contain multiple proteins and
RNA species with different functions. Loss of Ro60 and/
or La may disrupt these ribonucleoprotein particles lead-
ing to loss of function, some of which are intimatelyinvolved in structural RNA quality control. Loss of Ro60
or La may also produce other defects in polyadenylation
and/or degradation of structural RNAs. Further studies
will be required to better understand mechanistic rela-
tionships between Ro60 and/or La deficiency and polya-
denylation and processing of structural RNAs.
The relationship between deficiencies of Ro60 and La
proteins in RRMS, defective quality control of structural
RNAs in RRMS and disease pathogenesis is not immedi-
ately apparent. It is noteworthy that deletion of the Ro60
orthologue in mice results in selective development of a
Spurlock et al. Genome Biology  (2015) 16:58 Page 10 of 13lupus-like autoimmunity syndrome including increased
photosensitivity, membranoproliferative glomeruloneph-
ritis and production of autoantibodies suggesting that
one role of Ro60 may be to prevent certain forms of
autoimmunity [40]. Loss of Ro60 orthologues in various
species also results in aberrant responses to UV irradi-
ation, a form of cellular stress, defective ribosome bio-
genesis, including rRNA biogenesis, results in activation
of stress responses mediated via the p53 pathway [41].
Numerous studies have implicated aberrant stress re-
sponses in the genesis of autoimmunity. This interpret-
ation is consistent with our results that show that Ro60
and La deficiency are associated with human RRMS. It is
also noteworthy that therapy IFN-β1b (betaseron), a
common treatment for RRMS, restores levels of Ro60
and La proteins and polyadenylated structural RNA sub-
strates to near normal. As such, monitoring levels of
Ro60 and La proteins and polyadenylated structural
RNA substrates in response to therapy may be useful
predictors of disease activity or progression. It may also
be informative to determine how levels of Ro60 and La
proteins and polyadenylated structural RNA substrates
respond to newer therapies for RRMS, such as Tysabri™,
that are designed to keep mononuclear cells out of the
central nervous system [42]. Studies such as these may
define whether stimuli driving loss of Ro60 and La and
accumulation of polyadenylated structural RNAs are de-
rived from the central nervous system or the periphery.
It may seem unexpected that defects in expression of
Ro60 and La proteins and defective structural RNA pro-
cessing are seen in RRMS but not other autoimmune
diseases. In some respects this is reminiscent of the find-
ings that selective defects in RNA metabolism that are
thought to be causative for specific neurodegenerative
diseases [43-45]. In large part, these neurodegenerative
diseases result from death of specific classes of neurons
but are often caused by mutations in ubiquitously
expressed genes but produce a very specific neurologic
deficit. For example, spinal muscular atrophy is caused
by deletions or mutations in the gene that encodes sur-
vival of motor neuron 1 (SMN1) and the SMN1 protein
is ubiquitously expressed and plays a critical role in as-
sembly of the spliceosome and mRNA processing. Simi-
larly, defects in spliceosome integrity are also associated
with the motor neuron disease amyotrophic lateral
sclerosis. Other examples exist where defects in these
universal cellular processes give rise to unique neurode-
generative disorders. It is also relevant to note that we
have not examined defects in mRNA processing in
other inflammatory or autoimmune disorders and these
studies are in progress. It cannot be ruled out that in-
tegrity of mRNA processing is a common defect in
multiple autoimmune diseases that may arise from dif-
ferent molecular pathways.Conclusion
Origins of defects in expression of Ro60 and La proteins,
structural RNA processing, and mRNA processing in
RRMS may arise from inheritance or from environmen-
tal events or responses to environmental events. Our
cross-sectional analyses demonstrate that these defects
are not seen in subjects at the time of their initial CIS
event who go on to develop RRMS but are seen in sub-
jects at their initial diagnosis of RRMS. The period of
time between an initial CIS event and diagnosis of RRMS
is quite variable but can be up to five years (1 to 4). For
these reasons, we do not believe that defects described
here arise via inheritance but rather propose that environ-
mental events or responses to environmental changes are
causative. We cannot rule out the possibility that these de-
fects arise via somatic mutation and this will be the sub-
ject of future investigations. Further, if other cells,
especially cells within affected tissues in the CNS, exhibit
these defects is unknown and will be the subject of future
investigations.
Finally, biologic pathways that control surveillance and
quality control of structural RNAs are largely conserved
throughout evolution. Our results show that acquired
defects in these pathways are associated with human dis-
ease and may pave the way for a deeper understanding
of how these pathways may be involved in normal bio-
logic processes such as responses to extracellular and
intracellular stimuli, responses to various forms of stress,
and contributions to human disease.
Materials and methods
Study populations
Our patient cohort contained control subjects with no
major medical conditions, chronic or acute infections,
and no family history of autoimmune disease. Blood
samples in PaxGene tubes were obtained from (1) pa-
tients with clinically isolated syndrome prior to diagno-
sis of RRMS; (2) at the time of diagnosis of RRMS
before the onset of therapy; and (3) established RRMS
of >1 year’s duration on medications. We also analyzed
subjects (4) meeting the American College of Rheuma-
tology (ACR) clinical criteria of RA; (5) meeting the
ACR criteria for SLE; (6) NMO; and (7) PD. RRMS and
NMO samples were obtained from nine sites (AZ, CA,
MD, MA, MS, NY, SC, TN, TX)] in the United States
with the assistance of the Accelerated Cure Project. In
the established multiple sclerosis cohort, seven patients
were receiving glatiramer acetate (Copaxone) and 15
were on no immunomodulatory therapy. Unless other-
wise indicated, no established relapsing-remitting mul-
tiple sclerosis patients were receiving interferon-β1b
(Betserson). RA and SLE samples were collected from
three different sites in the USA (TN, TX, PA). Relevant
institutional board approval from all participating sites
Spurlock et al. Genome Biology  (2015) 16:58 Page 11 of 13was obtained. All subjects provided written informed
consent. Additional patient characteristics are summa-
rized in Additional file 1: Table S1.
siRNA knockdown and cell culture
Cells were cultured in RPMI 1640 medium supple-
mented with fetal bovine serum (FBS) at 10% (Jurkat) or
20% (THP-1), 1% penicillin/streptomycin, and 1% L-
glutamine at 37°C in a humidified atmosphere of 5%
CO2. Jurkat T cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). The
THP-1 monocytic cell line was from Dr. Jacek Hawiger
(Vanderbilt University Medical Center). Single, inventor-
ied silencer select siRNAs (Ambion) against each mRNA
were transfected into Jurkat T cells using the Amaxa Cell
Line Nucleofector Kit V (Lonza) or into THP-1 cells by
Lipofectamine RNAiMAX (Invitrogen).
RNA isolation, cDNA synthesis, and real-time PCR
Peripheral whole blood was drawn into PreAnalytiX
PaxGene tubes (VWR, West Chester, PA, USA). Cell
cultures were treated with Tri-Reagent (Molecular Re-
search Center). RNA was isolated following the supplied
protocol and purified with the RNEasy MinElute
Cleanup kit (Qiagen) and quantified using a Nano Drop
1000 spectrophotometer [46,47]. Complementary DNA
(cDNA) was reverse transcribed from total RNA using
the SuperScript III First-Strand Synthesis Kit (Life Tech-
nologies) using oligo-dT or random hexamer primers
and purified using the Qiagen QiaQuick PCR purifica-
tion kit. Real-time qPCR (Bio-Rad iCycleriQ Real Time
PCR System) was performed in duplicate using SYBR
green in 15 μL reaction volumes. Primers used in this
study are described in Additional file 3: Table S2.
Western blotting
Western blotting was performed as described previously
[48,49]. Briefly, peripheral blood mononuclear cells were
isolated from whole blood using BD Vacutainer Cell
Preparation Tubes. Whole cell lystates were resolved by
SDS polyacrylamide gel electrophoresis and transferred
to polyvinylidene fluoride (PVDF) membranes overnight
at 4°C. Membranes were washed and blocked using
Odyssey Blocking Buffer (Li-COR Biosciences, Lincoln,
NE, USA) for 1 h at room temperature. Membranes
were rinsed and incubated with primary antibodies over-
night at 4°C. Antibodies used in this study: monoclonal
mouse anti-SSB (ab75927; Abcam), polyclonal rabbit
anti-TROVE2 (NBP1-86998; Novus Biologicals), and
mouse monocloncal anti-actin (sc-8432; Santa Cruz Bio-
technology). Membranes were then washed and incubated
with fluorescently labled IRDye 700/800 antibodies diluted
in blocking buffer in the dark. Blots were washed and re-
suspended in TBS prior to scanning and bandquantification using the Li-COR Odyssey Infrared Imaging
System (Li-COR Biosciences, Lincoln, NE, USA).
RNA-Immunoprecipitation (RIP)
RIP analysis was performed as described previously
[50,51]. Briefly, Jurkat T cells were harvested, nuclei
isolated, lysed, and chromatin sheared, followed by in-
cubation with monoclonal mouse anti-SSB (ab 75927;
Abcam) or polyclonal rabbit anti-TROVE2 (NBP1-
86998; Novus) overnight at 4°C. Protein A/G beads
were added to the lysate and incubated at 4°C for an
additional 3 h. Beads were pelleted, supernatants har-
vested, and beads washed and suspended in Tri-
Reagent. RNA bound to the immunoprecipitate was
purified following the manufacturer’s supplied protocol
(Molecular Research Center).
RNA-seq sample preparation and data analysis
We extracted RNA from healthy controls (N = 8) and
established relapsing-remitting multiple sclerosis pa-
tients (N = 6) using PaxGene tubes according to the
manufacturer’s protocol. Library preparation was then
performed using the Illumina Tru-Seq RNA kit using
oligo-dT primers. RNA-sequencing was conducted in
the Vanderbilt Technologies for Advanced Genomics
(VANTAGE) core. One hundred bp paired-end reads
were generated with an Illumina HiSeq 2500. A quality
control step was initially performed on the raw data to
identify potential outliers before any advanced analysis
using tools such as Fastx Toolkit and FastQC [52]. The
RNA data were aligned with TopHat and gene expres-
sion levels were quantified using Cufflinks [53,54].
FPKM (fragments per kilobase per million reads) based
approaches (Cuffdiff ) were used to detect differentially
expressed genes [55]. False discovery rate (FDR <0.05)
was used for multiple test correction.
MatLab (version R2013a) was used to construct a
matrix of counts from the data. In particular, MatLab
functions included in the Bioinformatics Toolbox (for ex-
ample, getCounts, estimateBaseParams, computePVal,
and so on) were employed to extract counts on basepair
(bp) intervals specified by library GTF annotation files
or by customized un-annotated locations along each
chromosome in annotated exons and introns. These raw
counts were normalized using the medians of the sets
formed by the ratios of the raw counts and the non-zero
geometric mean of the raw counts on each interval.
These normalized counts were then used to perform the
statistical analysis comparing the control and multiple
sclerosis groups. In particular, the P values and adjusted
P values for the difference of the means of the two
groups were computed on each bp interval. The
Benjamini-Hochberg procedure was used to find the ad-
justed P value and correct for FDRs from multiple
Spurlock et al. Genome Biology  (2015) 16:58 Page 12 of 13sampling. Next, the log2 of the ratio of the mean nor-
malized multiple sclerosis counts to the mean normalize
control counts was computed for bp intervals that had
non-zero geometric means. Lastly, bp intervals where
the adjusted P value was less than a prescribed number
(for example, 0.01) and the absolute value of the log2 ra-
tio was larger than a second prescribed number (for ex-
ample, 4) were then selected for further analysis. Output
from MatLab calculations were inputted into Mathema-
tica (version 9.0.1) whose GeonomeData database was
used to further explore coding and non-coding regions
along the chromosomes. We considered loss of one or
more exons at the 5’ end of an individual mRNA tran-
script to be an example of 5’ mRNA shortening and loss
of one or more exons at the 3’ end of an individual
mRNA to be an example of 3’ mRNA shortening. Intron
retention was defined as gain of specific RNA transcripts
within introns.Statistical analysis
Data are expressed as the mean ± SD of three or more in-
dependent experiments. Significance was determined by
Student’s t-test using GraphPad Prism Software (La Jolla,
CA, USA). P values <0.05 were considered significant.Data availability
The RNA-sequencing data used in this study are access-
ible through NCBI’s Gene Expression Omnibus using
accession code GSE66573.Additional files
Additional file 1: Table S1. Summary of patient characteristics.
Additional file 2: Figure S1. RNA-immunoprecipitation analysis of
target mRNA binding to Ro60 and La proteins. Ro60 or La proteins were
immunoprecipitated with specific antibodies. Levels of each mRNA (X-axis)
were determined by quantitative PCR using exon-specfic primers described
in Figure 4F. Result are expressed as fraction of the total of each mRNA
unbound or recovered in the Ro60 or La immunoprecipitates (± S.D).
Additional file 3: Table S2. Primers used in quantitative PCR reactions.Abbreviations
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